DAC-1522 / DaCure Therapeutics - LARVOL DELTA

DAC-1522, a Trop2-directed degrader-antibody conjugate, overcomes resistance to conventional ADCs (EACR 2026) - "By integrating antigen targeting with selective protein degradation, DAC-1522 demonstrates superior antitumor efficacy and a differentiated therapeutic profile compared to currently approved Trop2-directed ADCs, highlighting its significant potential for further development."

ADC • Targeted Protein Degradation

DAC-1522: A novel Trop2-targeting degrader-antibody conjugate for precision oncology (AACR 2026) - "Notably, DAC-1522 maintained robust activity in an Enhertu-acquired drug resistance model, whereas Enhertu and SKB264 showed markedly compromised efficacy, highlighting its potential to overcome resistance associated with conventional ADC therapies. In vivo, a single intravenous dose of DAC-1522 induced complete tumor regression in the BXPC-3 xenograft model without body weight loss.ConclusionDAC-1522 represents a novel Trop2-targeting DAC that demonstrates superior in vivo antitumor efficacy and the ability to overcome drug resistance, underscoring its promise as a therapeutic candidate for TROP2-positive malignancies."

Oncology

Discovery and characterization of DAC-1522, a novel Trop2-targeting degrader-antibody conjugate for precision oncology (AACR 2025) - "Despite the clinical success of Trop2-targeting ADCs like IMMU-132 (sacituzumab govitecan-hziy), their dependence on topoisomerase inhibitors as payloads has exposed significant limitations, particularly in addressing both intrinsic and acquired drug resistance. No obvious safety concerns were observed. These findings support further preclinical and clinical development of DAC-1522 as a highly promising therapeutic candidate for the Trop2-expressing cancers."

Oncology • Pancreatic Cancer • Solid Tumor • TACSTD2

Discovery of DAC-1522, a novel Trop2-targeting degrader-antibody conjugate for precision oncology (EACR 2025) - "Our findings strongly support the further development of DAC-1522 as a highly promising therapeutic candidate for Trop2-expressing cancers."

Oncology • Pancreatic Cancer • Solid Tumor • TACSTD2